Clinical studies

Efficacy and tolerability of Vitamindermina restorative moisturising cream in patients with xerotic or atopic skin.

PANEL
14 subjects (ages 16–83, average age 46.7 years) with xerotic skin (4) or atopic skin (10).

TREATMENT
2 applications/day of Vitamindermina Cream for 28 days.

CLINICAL EVALUATIONS
Reduction in:
-xerosis, scaling, tightness, cracks/fissures, excoriations, erythema, itching (scored 0=absent; 1=mild; 2=moderate; 3=severe; 4=very severe)
-Eczema Area and Severity Index (EASI) in patients with atopic dermatitis
-VAS xerosis in patients with xerotic skin (visual analogue scale 0–10)

SUBJECTIVE EVALUATIONS
-Improvement in quality of life
-Overall treatment efficacy
-Ease of use and cosmetic appeal
-Tolerability

CONTROLS
T0 baseline, T1 (14 days), T2 (28 days)

Efficacy, tolerability and sensory appeal of Vitamindermina Anti-Chafing Gel
A solution to prevent irritation caused by chafing and improve the quality of life for obese patients.

PANEL
83 obese patients (ages 19–79, average age 50.7 years):
• 28% with obesity grade 1 (30< BMI <34,9)
• 29% with obesity grade 2 (35< BMI <39,9)
• 43% with obesity grade 3 (BMI > 40)

TREATMENT
2–3 applications/day, as required, on affected areas for 28 days.

EVALUATIONS
Self-assessment
• Burning/pain and itching (Visual Analogue Scale – VAS 0–10)
• Discomfort related to clothing (score 0–3)
• Cosmetic appeal (insufficient – sufficient – good – excellent)
• Overall evaluation (insufficient – sufficient – good – excellent)
Clinical assessment
• Tolerability

ENDPOINT Verify a reduction in discomfort parameters after 28 days of use.